Inter Parfums Earnings Preview

Inter Parfums (NASDAQ:IPAR) is set to give its latest quarterly earnings report on Monday, 2022-08-01. Here's what investors need to know before the announcement. Analysts estimate that Inter Parfums will report an earnings per share (EPS) of $0.76.

Inter Parfums (NASDAQ:IPAR) is set to give its latest quarterly earnings report on Monday, 2022-08-01. Here’s what investors need to know before the announcement.

Analysts estimate that Inter Parfums will report an earnings per share (EPS) of $0.76.

Inter Parfums bulls will hope to hear the company to announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

Last quarter the company beat EPS by $0.22, which was followed by a 12.69% drop in the share price the next day.

Here’s a look at Inter Parfums’s past performance and the resulting price change:

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate 0.88 -0.20 0.68 0.23
EPS Actual 1.10 -0.04 1.20 0.71
Price Change % -12.69% 1.43% 0.01% -1.88%

eps graph

Stock Performance

Shares of Inter Parfums were trading at $82.56 as of July 28. Over the last 52-week period, shares are up 7.83%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

To track all earnings releases for Inter Parfums visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

This Cannabinoids-Focused Pharma Co. Sees 50% YoY Surge In Revenue In 2023, Trims Losses

Cannabinoids-focused pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Wednesday its financial results for the full year and three months ended Dec. 31, 2023. Net revenue grew to CA$33 million ($24.3 million), from CA$22.1 million in 2022, representing roughly a 50% year-over-year increase. "Over the years we have invested in our infrastructure as a high quality and high-capacity pharmaceutical grade manufacturer, allowing us to grow sales with new opportunities and markets, without additional investment into capital or resources," David Pidduck said. "We are proud of the work completed in 2023 and excited about the future of MediPharm Labs."

MEDIF